Expanding access to HAART: A cost-effective approach for treating and preventing HIV

AIDS

Volumn 24, Issue 12, 2010, Pages 1929-1935

  Johnston, Karissa M ^a   Levy, Adrian R ^b   Lima, Viviane D ^c   Hogg, Robert S ^c   Tyndall, Mark W ^c   Gustafson, Paul ^a   Briggs, Andrew ^d   Montaner, Julio S ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c HIV   (Canada)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Economic evaluation; HAART as prevention; HIV prevention; Mathematical model

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 77954763358     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833af85d     Document Type: Article

References (42)

1. Public Health Agency of Canada. HIV/AIDS Epi Updates 2007. Ottawa: Public Health Agency of Canada 2007.
2. BC Ministry of Health Planning. Priorities for action in managing the HIV epidemics: 2003-2007. Victoria: BC Ministry of Health Planning 2003.
3. World Health Organization. 2007 Report on the global AIDS epidemic. Geneva: WHO; 2007.
4. Tyndall MW, Craib KJP, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28:351-357.
5. Craib KJP, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Can Med Assoc J 2003; 168:19-24.
6. Spittal PM, Craib KJP, Wood E, Laliberte N, Li K, Tyndall MW, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. Can Med Assoc J 2002; 166:894-899. (Pubitemid 34275509)
7. Spittal PM, Hogg RS, Li K, Craib KJ, Recsky M, Johnston C, et al. Drastic elevations in mortality among female injection drug users in a Canadian setting. AIDS Care 2006; 18:101-108.
8. Wood E, Montaner JSG, Bangsberg DR, Tyndall MW, Strathdee SA, O'Shaughnessy MV, et al. Expanding access to HIV anti-retroviral therapy among marginalized populations in the developed world. AIDS 2003; 17:2419-2427.
9. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
10. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med 1999; 340:1672-1674.
11. Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active anti-retroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
12. Hogg RS, Rhone SA, Yip B, Sherlock C, Conway B, Schechter MT, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12:279-284.
13. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li CJ, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1.N EnglJ Med 2000; 342:921-929.
14. Cohen MS, Gay C, Kashuba ADM, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Inter Med 2007; 146:591-601.
15. Granich R, Gilks C, Dye C, De Cock K, Williams B. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
16. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006; 6:171-177.
17. Hogg RS, Yip B, Kully C, Craib KJP, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999; 160:659-665
18. British Columbia Centre for Disease Control. STI/HIV Prevention and Control Annual Report. Vancouver: British Columbia Centre for Disease Control; 2008.
19. Wilson D. HIV epidemiology: a review of recent trends and lessons. Global HIV/AIDS Program. Washington, District of Columbia: The World Bank; 2006.
20. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnesy MV, Montaner JSG. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003; 17:711-720.
21. Wood S. Generalized additive models: an introduction with R. Boca Raton: Chapman & Hall; 2006.
22. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing healthcare utilization and costs. Annu Rev Public Health 1999; 20:125-144.
23. Richman D. Human immunodeficiency virus. London: International Medical Press; 2003.
24. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci USA 2007; 104:17441-17446.
25. Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V, et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355:1131-1137.
26. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, et al. Expanded accessto highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67.
27. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
28. Canadian Institute for Health Information. National Health Expenditure Trends: 1975-2006. Ottawa: Canadian Institute for Health Information 2006.
29. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986; 5:1-30.
30. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decision Mak 2002; 22:27-38.
31. Organization for Economic Development and Co-operation (OECD). Health Data 2007. Paris: Organization for Economic Development and Co-operation; 2007.
32. Zethraeus N, Johannesson M, Jonsson B, Lothgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeco-nomics 2003; 21:39-48.
33. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-481.
34. Koerkamp BG, Hunink MGM, StijnenT,Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decision Mak 2007; 27:101-111.
35. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13:405-415.
36. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493.
37. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3:493-504.
38. Salomon JA, Hogan DR. Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS 2008; 22:S149-S159.
39. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: Implications for prevention strategies. J Infect Dis 1996; 174:S201-S213.
40. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15:1295-1310.
41. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
42. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43:451-457.